Sjögren's disease & overlap diseases
Pregnancy outcomes in women with primary Sjögren's syndrome: an analysis of data from the multicentre, prospective, GR2 study
Main finding · Adverse pregnancy outcomes, matched controlled studyResult — go to the resultOdds ratio 1.31 95% CI 0.53–2.98Authors' conclusion
Pregnancies in women with primary Sjögren's syndrome had very good prognoses for mothers and fetuses, with no overall increase in adverse pregnancy outcome risk compared with the general population.
Study context
- Population
- Women with pSS (ACR/EULAR 2016 criteria) who conceived before March 2021 with an ongoing pregnancy at 12 weeks of gestation, GR2 registry, France106 pregnancies in 96 women with pSS
- Participants
- 105 vs 420
- Exposure
- Pregnancies in women with pSS vs matched general-population controls
- pSSn = 105
- Matched controlsn = 420reference
- Outcome
- Adverse pregnancy outcomes:
- Fetal or neonatal death
- Placental insufficiency leading to preterm delivery [<37 weeks]
- Small-for-gestational-age birthweight
Methodological detailsmulticentre, matched controlled comparison with general population
- Multicentre
- Matched controlled comparison with general population
Main finding
As reported in the abstract
Adverse pregnancy outcomes, matched controlled study
Odds ratio
1.31
95% CI 0.53–2.98
P = 0.52
Events by group
pSSvs Matched controls
OR 1.31 (95% CI 0.53–2.98); P = 0.52
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| aPL positivity, pregnancies with vs without adverse outcomes (n=55 with aPL data) | P = 0.023 |
- pSS flare (≥3-point increase in ESSDAI), pregnancies included at week 18 or earlier
- 13% · 12
- pSS flare (≥3-point increase in ESSDAI), pregnancies included at week 18 or earlier: 93 pregnancies included at week 18 of gestation or earlier
- aPL positivity, pregnancies with vs without adverse outcomes (n=55 with aPL data): With adverse outcomes 50%
- aPL positivity, pregnancies with vs without adverse outcomes (n=55 with aPL data): Without adverse outcomes 4%
pSS flare (≥3-point increase in ESSDAI), pregnancies included at week 18 or earlier
- No baseline parameters were associated with pSS flare
Adverse pregnancy outcomes in the GR2 cohort (twin pregnancies and medical termination excluded)
- Adverse pregnancy outcomes among the remaining 88 pregnancies
- six (7%)
- Four twin pregnancies and one medical termination excluded
aPL positivity, pregnancies with vs without adverse outcomes (n=55 with aPL data)
- Anti-RNP antibody positivity more frequent among pregnancies with adverse outcomes, not statistically significant
Original publication
Pregnancy outcomes in women with primary Sjögren's syndrome: an analysis of data from the multicentre, prospective, GR2 study. Lancet Rheumatol. Published 8 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →